drugset / Trial / NCT03711279
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the efficacy of SHR-1210 plus Apatinib versus AMD plus IFO in participants with soft tissue sarcoma.
Timeline
- Start
- 2018-11-22
- Primary completion
- 2021-06-21
- Completion
- 2021-06-21
Outcome
Outcome not reported
Stopped (Business): “Sponsor R \& D Strategy Adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ADM | Unknown | 60 mg/m2 | — |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Comparator | IFO | Unknown | 2 g | — |
| Subject | Rivoceranib | Small molecule | 500 mg | — |